证券代码：300015 股票简称：爱尔眼科 公告编号：2026-003 爱尔眼科医院集团股份有限公司 关于使用部分闲置自有资金进行现金管理的实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日召开第六届董事会第三十二次会议，审议通过了《关于使用部分闲置自有资金 进行现金管理的议案》，同意公司在保证日常经营资金需求和资金安全的前提下， 使用不超过人民币 15 亿元的闲置自有资金购买安全性高、流动性好、风险性低 的理财产品，期限为自公司第六届董事会第三十二次会议决议之日起 12 个月。 在上述额度及期限内，资金可循环滚动使用，由公司财务中心负责具体购买事宜。 上述内容详见公司 2025 年 3 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露 的相关公告。 根据上述决议，公司于近期办理了投资理财业务。现就具体事项公告如下： 风险等级：中低风险 认购金额：20,000 万元 关联关系说明：公司与中信证券股份有限公司不存在关联关系 2、产品名称：中信证券财富私享投 ...

Core Viewpoint - Tianjin Jiuan Medical Electronics Co., Ltd. has recently acquired a piece of industrial land in Nankai District, marking it as the fourth industrial land transaction in the area since 2025, following companies like Jiuzhoutong Pharmaceutical Group and Aier Eye Hospital Group [1] Group 1: Industrial Land Development - Nankai District is focusing on simultaneous promotion of investment attraction and revitalization of idle assets, aiming to gather the development of science and technology innovation industries [1] - The district's strategy includes optimizing spatial layout into a "one core, two axes, three zones" structure, with the Tiankai Higher Education Science and Technology Innovation Park as the innovation engine [1] Group 2: Modern Industrial System - Nankai District has proposed a "3+2" modern urban industrial system, emphasizing three main industries: technology services, intelligent manufacturing, and biomedicine, along with two characteristic industries: cultural tourism and commercial services [2] - The technology service sector will leverage resources from universities and key laboratories to create a comprehensive service system covering R&D, technology transfer, concept validation, intellectual property, and technology finance [2]

Group 1 - Tianjin Jiuan Medical Electronics Co., Ltd. has recently acquired an industrial land in Nankai District, marking it as the fourth industrial land transaction in the area since 2025, following companies like Jiuzhoutong Pharmaceutical Group and Aier Eye Hospital Group [1] - Nankai District is focusing on synchronizing investment attraction and revitalization efforts to enhance the development of the science and technology innovation industry [1] - The district aims to optimize its spatial layout into a structure of "one core, two axes, and three zones," with the Tiankai Higher Education Science and Technology Innovation Park as the innovation engine [1] Group 2 - Nankai District has proposed to develop a "3+2" modern urban industrial system, focusing on three main industries: technology services, intelligent manufacturing, and biomedicine, along with two characteristic industries: cultural tourism and commercial services [2] - The district plans to accelerate the transformation of old and new driving forces by strengthening its leading industries and nurturing future industries [2] - The technology service industry will leverage resources from universities and key laboratories to create a comprehensive service system covering research and development, technology transfer, concept validation, intellectual property, and technology finance [2]

有投资者在互动平台向爱尔眼科提问："中国244小时免签政策后，很多欧美发达国家外国人发现中国就 医成本低还效率高，导致越来越多外国人到中国看病，希望贵公司能抓住机会把握时机扩大公司全球影 响力！作为全国眼科龙头，请问贵公司对此有哪些计划？准备如何扩大艾尔眼科国际医疗部对外国患者 的影响力吸引力？自244免签政策后，贵公司国际医疗部外国患者年或月增长率是多少？营业额相比国 内有没有明显提高？谢谢！" 针对上述提问，爱尔眼科回应称："谢谢您对公司的关注。公司在中心城市的医院设有国际诊疗部或特 需部，提供符合国际标准的服务。中国就医的优势越来越明显，公司将依托品牌规模及国际网络，不断 优化诊疗流程，提高就诊便利性，扩大国际医疗部的影响力。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

证券之星消息，1月13日医疗服务板块较上一交易日上涨4.15%，诺思格领涨。当日上证指数报收于 4138.76，下跌0.64%。深证成指报收于14169.4，下跌1.37%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301333 | 诺思格 | 76.48 | 20.01% | 5.52万 | | 3.97亿 | | 301257 | 電影斯 | 72.24 | 20.00% | 2.29万 | | 1.56亿 | | 301230 | 泓博医药 | 56.64 | 20.00% | 5.72万 | | 3.24亿 | | 301060 | 兰卫医学 | 13.28 | 19.96% | 1 35.21万 | | 4.41亿 | | 300404 | 博济医药 | 12.92 | 19.96% | 62.71万 | | 7.76亿 | | 300244 | 迪安诊断 | 29.16 | 11.90% | 151.60万 | | 46.46亿 | ...

1月13日，全球领先的眼内屈光矫正技术迎来新的里程碑。在南京爱尔眼科医院举行的授牌仪式上，瑞 士STAAR Surgical公司正式授予南京爱尔眼科医院"EVO+ ICL (V5) 首批临床应用合作中心"资质，同时 授予医院屈光手术科主任熊娟"EVO+ ICL (V5) 认证手术医师"证书。这标志着该项以优化夜间视觉为核 心优势的国际新一代近视矫正技术，在南京地区获得了官方的临床应用许可与专家认证，江苏地区的近 视患者将能更便捷地享受到与国际同步的"日夜高清"视觉体验。 ▲王林农院长与熊娟主任代表南京爱尔眼科医院接受EVO+ ICL (V5) 首批临床应用合作中心授牌 就在不久前于上海举行的2026"海上之光"学术会议上，爱尔眼科集团凭借其强大的临床实力，一举荣获 "EVO+ ICL (V5) 临床研究联盟成员单位"与"首批临床应用专家"双重行业认证。南京爱尔眼科医院此次 获得的认证，正是集团战略赋能与区域技术实力的集中体现，实现了从集团引领到医院落地的完整闭 环。 ▲爱尔眼科荣获EVO+ ICL(V5) 双重重磅认证 技术革新：引领屈光手术进入"日夜更+高清"时代 ▲熊娟主任通过3D导航显微镜进行EVO+ ...

Core Viewpoint - The company emphasizes the potential of robotics in the medical field, highlighting improvements in effectiveness, efficiency, and cost reduction, while maintaining that expert operation and patient-centered ethics are paramount [1] Group 1: Technological Advancements - The rapid development of technology is paving the way for significant advancements in medical robotics [1] - The introduction of the new generation of robotic equipment, such as the Zeiss VISUMAX800 and the SMILEpro, is planned for multiple hospitals by 2025 [1] Group 2: Operational Milestones - The Changsha Medical Center successfully performed Hunan Province's first eye surgery using a robotic-assisted technique for precise subretinal injection [1]

爱尔眼科医院集团股份有限公司 章 程 二Ｏ二五年十一月 1 | | | | | | 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共 和国证券法》（以下简称《证券法》）和其他有关规定，制订本章程。 第二条 爱尔眼科医院集团股份有限公司系依照《公司法》和其他有关规定 成立的股份有限公司（以下简称"公司"）。 公司于2007年12月5日由爱尔眼科医院集团有限公司整体变更设立，在湖南 省 市 场 监 督 管 理 局 登 记 注 册 ， 取 得 营 业 执 照 ， 统 一 社 会 信 用 代 码 ： 91430000745928604G。 | | | 第三条 公司于2009年9月25日经中国证监会批准，首次向社会公众发行人民 币普通股3,350万股，于2009年10月30日在深圳证券交易所上市。 第四条 公司注册名称：爱尔眼科医院集团股份有限公司。 英 文 名 称：Aier Eye Hospital Group Co.,Ltd. 第五条 公司住所：长沙市天心区芙蓉南路一段188号爱尔大厦。 第六条 公司注册资本为 ...

根据会议决议，公司于近日完成了市场主体备案手续，具体内容详见与本公 告同日披露的《公司章程》。 特此公告。 爱尔眼科医院集团股份有限公司董事会 关于完成《公司章程》备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 11 月 10 日召开第六届董事会第四十四次会议、2025 年 11 月 27 日召开 2025 年第三次临 时股东大会，审议通过了《关于修订<公司章程>并办理市场主体变更登记的议案》。 具体内容详见公司于 2025 年 11 月 11 日披露的《关于修订<公司章程>并办理市 场主体变更登记的公告》(公告编号：2025-085)。 证券代码：300015 股票简称：爱尔眼科 公告编号：2026-002 爱尔眼科医院集团股份有限公司 2026 年 1 月 12 日 ...